- Clarification 09 October 2021
How antiviral pill molnupiravir shot ahead in the COVID drug hunt
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Updates & Corrections
Clarification 09 October 2021: This story was updated to clarify that the two Indian drugmakers testing a generic version of molnupiravir did so independently of Merck, and to add comments from Merck indicating that moderate cases of COVID-19 in India are defined as being more severe than those in the United States.
Beigel, J. H. et al. N. Engl. J. Med. 383, 1813-1826 (2020).
Sheahan, T. P. et al. Sci. Transl. Med. 12, eabb5883 (2020).
Cox, R. M. et al. Nature Microbiol. 6, 11-18 (2021).